patritumab

This page shows the latest patritumab news and features for those working in and with pharma, biotech and healthcare.

Daiichi gets breakthrough status for pre-NDA leukaemia drug

of HER3 inhibitor patritumab in combination with Roche’s EGFR drug Tarceva (erlotinib) in the same indication on disappointing efficacy data. ... Patritumab is still in mid-stage testing for head and neck cancer.

Latest news

Daiichi pulls study of patritumab in lung cancer

Daiichi Sankyo has halted a late-stage trial of its HER3 inhibitor patritumab after seeing no evidence of efficacy at an interim analysis. ... This particular result does not directly affect the science of patritumab in other settings," said Yver.
Daiichi Sankyo to shut down German antibody unit U3

cancer. . U3 Pharma's lead candidate patritumab (U3-1287), an anti-HER3 antibody in clinical trials for non-small cell lung cancer (NSCLC), breast cancer and head and neck cancer, was

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

claire@dovetailstrategies.com

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

Improve clinical trials through patient journey mapping: Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping: Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much: Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...